Vanguard Fiduciary Trust
OTLK icon

Vanguard Fiduciary Trust’s Outlook Therapeutics OTLK Stock Holding History

Vanguard Fiduciary Trust’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.05M Buy
661,664
+485,135
+275% +$301K ﹤0.01% 3001
2026
Q1 		$36.4K Buy
+176,529
New +$76.3K ﹤0.01% 3877

Other funds holding OTLK

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
GWM
Gilpin Wealth Management Denver, Colorado $145M AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return

Vanguard Fiduciary Trust's OTLK Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Outlook Therapeutics (OTLK) stake by 275% in Q2 2026, buying an estimated $301K and bringing the position to 661,664 shares worth $1.05M. The position accounts for ﹤0.01% of the portfolio, ranked #3001.

Vanguard Fiduciary Trust first reported a position in OTLK in Q1 2026 and has held it in 2 quarters since. 64 funds tracked by Wall St. Rank hold OTLK as of Q2 2026.

  • Vanguard Fiduciary Trust held 661,664 shares of Outlook Therapeutics worth $1.05M as of Q2 2026.
  • Vanguard Fiduciary Trust bought 485,135 Outlook Therapeutics shares in Q2 2026, an estimated $301K.
  • Outlook Therapeutics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #3001 holding.
  • Vanguard Fiduciary Trust first reported a position in Outlook Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 64 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.